Want help reviewing this study?
Study ID: NCT06159673. We help you review the study, but cannot decide medical eligibility.
RecruitingNCT06159673
ACP-204 in Adults With Alzheimer's Disease Psychosis
A short description of this study’s research objective has not yet been verified.
Medication studyAges 55–95Multiple countriesSchizophrenia
Understand this study
Who could participate?
Listed age limits: 55 years to 95 years.
- Listed locations
- Chandler, United States · Scottsdale, United States and 100 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 14, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 1,074
- Sponsor
- ACADIA Pharmaceuticals Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- United States, France, Brazil, ...
- Age range
- From 55 Years to 95 Years
- Official registry ID
- NCT06159673
- Official title
- A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis
Recruitment & locations
RecruitingChandler, United States · Scottsdale, United States · Anaheim, United States
99 more locations
- Costa Mesa, United States
- Fresno, United States
- Garden Grove, United States
- Pasadena, United States
- Aventura, United States
- Daytona Beach, United States
- Doral, United States
- Hialeah, United States
- Miami, United States
- Miami Beach, United States
- Miami Gardens, United States
- Miami Lakes, United States
- Orlando, United States
- Tampa, United States
- West Palm Beach, United States
- Atlanta, United States
- Elgin, United States
- Shreveport, United States
- Gaithersburg, United States
- Rochester Hills, United States
- St Louis, United States
- Lincoln, United States
- Amherst, United States
- Rochester, United States
- Syracuse, United States
- The Bronx, United States
- Beachwood, United States
- Centerville, United States
- Dayton, United States
- Abington, United States
- Cypress, United States
- Houston, United States
- Stafford, United States
- Webster, United States
- Joinville, Brazil
- Brasília, Brazil
- Curitiba, Brazil
- Passo Fundo, Brazil
- Porto Alegre, Brazil
- Rio de Janeiro, Brazil
- São Bernardo do Campo, Brazil
- São Paulo, Brazil
- Cherven Bryag, Bulgaria
- Kardzhali, Bulgaria
- Pazardzhik, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Stara Zagora, Bulgaria
- Antofagasta, Chile
- Santiago, Chile
- Kladno, Czechia
- Prague, Czechia
- Brno, Czechia
- Choceň, Czechia
- Rychnov nad Kněžnou, Czechia
- Bron, France
- Colmar, France
- Dijon, France
- Limoges, France
- Lyon, France
- Paris, France
- Rouen, France
- Toulouse, France
- Tours, France
- Vandœuvre-lès-Nancy, France
- Brescia, Italy
- Cefalù, Italy
- Isernia, Italy
- Milan, Italy
- Roma, Italy
- Salerno, Italy
- Torino, Italy
- Tricase, Italy
- Monterrey, Mexico
- Coahuila, Mexico
- Estado de México, Mexico
- Mazatlán, Mexico
- Mexico City, Mexico
- Nuevo León, Mexico
- San Luis Potosí City, Mexico
- Sinaloa, Mexico
- Belgrade, Serbia
- Gornja Toponica, Serbia
- Kovin, Serbia
- Kragujevac, Serbia
- Niš, Serbia
- Novi Kneževac, Serbia
- Sombor, Serbia
- Valjevo, Serbia
- Incheon, South Korea
- Seoul, South Korea
- Seville, Spain
- Zamora, Spain
- Kaohsiung City, Taiwan
- New Taipei City, Taiwan
- Tainan, Taiwan
- Taipei, Taiwan
- Czechia
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is ACADIA Pharmaceuticals Inc.
Does this study involve medication?
Yes. The study involves medication, including ACP-204 and Placebo.
Who can participate?
Listed age limits: 55 years to 95 years.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
RecruitingNCT07369154
52-week Open Label Safety-Tolerability Study
This study is recruiting. It focuses on schizophrenia and currently lists participation information in the United States.
RecruitingNCT06821945
A study Safety and Efficacy of Olanzapine Titration Schedule in people with Schizophrenia
This study is recruiting. It focuses on schizophrenia and currently lists participation information in South Korea.
RecruitingEUCTR 2021-000350-26
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.